Why TIXiMED’s TIX100 data highlights a growing therapeutic gap after GLP-1 weight-loss treatment
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
What Veru Inc.’s Phase 2b PLATEAU trial signals about the evolution of combination obesity drugs
Veru Inc. launches Phase 2b PLATEAU trial combining enobosarm with semaglutide for obesity. Discover what it means for next-generation weight-loss drugs.
Can Sciwind Biosciences’ ecnoglutide challenge conventional GLP-1 drugs in the expanding obesity market?
China approves Sciwind Biosciences’ ecnoglutide for weight management. Discover what the biased GLP-1 mechanism could change in the obesity drug race.
Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?
Novo Nordisk’s semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.